Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Arecor Therapeutics PLC ( (GB:AREC) ) is now available.
Arecor Therapeutics PLC and Sequel Med Tech LLC are set to host a virtual fireside panel discussion on January 7, 2025, focusing on the treatment journey for diabetes patients and the future of insulin delivery systems. The discussion will highlight Arecor’s AT278 insulin and Sequel’s twiist device, exploring their co-development and the potential advancements in the diabetes/insulin pump sector. This event underscores Arecor’s strategic positioning in advancing diabetes care and its collaboration with Sequel to innovate in the insulin delivery market.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £76.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics’ score is driven by positive corporate events, including strategic partnerships and IP expansion, which bolster its market position. However, financial performance challenges, such as ongoing losses and cash flow issues, weigh heavily on the overall score. Technical analysis and valuation present a neutral outlook, reflecting the typical risks and opportunities in the biotech sector.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics PLC is a clinical stage biopharmaceutical company based in Cambridge, UK, specializing in drug development and delivery for diabetes and other cardiometabolic diseases. Utilizing its proprietary Arestat® technology platform, Arecor is developing a range of products, including AT278, an ultra-concentrated, ultra-rapid acting insulin. The company is also working on a novel oral delivery platform for peptides targeting obesity and diabetes markets. Arecor is listed on AIM (AIM: AREC).
Average Trading Volume: 33,857
Technical Sentiment Signal: Buy
Current Market Cap: £27.94M
See more insights into AREC stock on TipRanks’ Stock Analysis page.